Tempus broadens collaboration with BMS for clinical trials
Summary
Tempus has expanded its strategic collaboration with Bristol Myers Squibb to use the Tempus Lens analytical platform, multimodal de‑identified real-world data, and AI to optimise clinical trial design and improve Probability of Technical & Regulatory Success (PTRS) across initial programmes. The initiative initially targets solid tumour oncology projects (including colon, lung, and prostate) and also extends into neuroscience, notably Alzheimer’s disease. Tempus says its multimodal data lets teams connect clinical records to molecular subtypes to uncover biological signals, stratify patient groups, and test trial assumptions more precisely. BMS highlights the partnership’s role in pressure-testing development assumptions and designing studies with higher chances of technical and regulatory success.
Classifications
AskAI Classifications
LabelsLinked Companies
